Table 2.
Cell line | CHL-1 | SK-MEL-23 | ||
---|---|---|---|---|
MEK inhibitor | Selumetinib | Trametinib | Selumetinib | Trametinib |
Fold increase in SF50 | 6.71 ± 1.30 | 6.85 ± 2.42 | 2.94 ± 0.40 | 2.48 ± 0.44 |
p-value | 0.0072 | 0.0605 | 0.0048 | 0.02 |
The table shows mean ± SEM fold increase in SF50 values in DUSP4-depleted CHL-1 and SK-MEL-23 cells (n = 6 in each case; data analysed using two-tailed t test).